{"id":"hydrea-hydroxyurea","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression (anemia, leukopenia, thrombocytopenia)"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Elevated uric acid (hyperuricemia)"},{"rate":null,"effect":"Megaloblastic anemia"},{"rate":null,"effect":"Skin ulceration and atrophy"},{"rate":null,"effect":"Hepatotoxicity"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By blocking the enzyme ribonucleotide reductase, hydroxyurea depletes the deoxyribonucleotide pool needed for DNA synthesis, thereby slowing or halting cell division. This mechanism makes it effective against rapidly proliferating cancer cells and also increases fetal hemoglobin production in sickle cell disease, reducing sickling episodes. The drug is a non-selective cytotoxic agent that affects both malignant and normal dividing cells.","oneSentence":"Hydroxyurea inhibits ribonucleotide reductase, reducing deoxyribonucleotide synthesis and slowing DNA replication in rapidly dividing cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:33:02.654Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic myeloid leukemia (CML)"},{"name":"Polycythemia vera"},{"name":"Essential thrombocythemia"},{"name":"Sickle cell disease (to reduce vaso-occlusive crises)"}]},"trialDetails":[{"nctId":"NCT06439082","phase":"PHASE3","title":"A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-10-24","conditions":"Sickle Cell Disease","enrollment":315},{"nctId":"NCT06923111","phase":"","title":"PASS of Xromi Comparing Safety and Effectiveness in Children Under 2 Years With Sickle Cell Disease [PRECISE PASS]","status":"RECRUITING","sponsor":"Nova Laboratories Limited","startDate":"2025-06-09","conditions":"Sickle Cell Disease","enrollment":180},{"nctId":"NCT03500731","phase":"PHASE1, PHASE2","title":"Lung and Bone Marrow Transplantation for Lung and Bone Marrow Failure","status":"RECRUITING","sponsor":"Paul Szabolcs","startDate":"2018-04-19","conditions":"Idiopathic Pulmonary Fibrosis, Emphysema or COPD","enrollment":8},{"nctId":"NCT06326190","phase":"PHASE2","title":"177Lu-DOTATATE for Recurrent Meningioma","status":"RECRUITING","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2025-03-10","conditions":"Recurrent Meningioma","enrollment":136},{"nctId":"NCT03653338","phase":"PHASE1, PHASE2","title":"T-Cell Depleted Alternative Donor Bone Marrow Transplant for Sickle Cell Disease (SCD) and Other Anemias","status":"RECRUITING","sponsor":"Paul Szabolcs","startDate":"2018-08-02","conditions":"Sickle Cell Anemia, Beta-thalassemia Major, Diamond-blackfan Anemia","enrollment":5},{"nctId":"NCT03806452","phase":"PHASE2","title":"SIKAMIC (SIklos on Kidney Function and AlbuMInuria Clinical Trial)","status":"COMPLETED","sponsor":"Theravia","startDate":"2019-05-28","conditions":"Sickle Cell Disease","enrollment":86},{"nctId":"NCT03263559","phase":"PHASE2","title":"Haploidentical Bone Marrow Transplantation in Sickle Cell Patients (BMTCTN1507)","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2017-10-03","conditions":"Sickle Cell Disease","enrollment":95},{"nctId":"NCT06464458","phase":"NA","title":"Optimizing the Management of Sickle Cell Patients on Hydroxyurea: The Value of Therapeutic Pharmacological Monitoring","status":"RECRUITING","sponsor":"University Hospital, Strasbourg, France","startDate":"2023-02-08","conditions":"Sickle Cell Disease","enrollment":30},{"nctId":"NCT04116502","phase":"PHASE3","title":"MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia Vera","status":"RECRUITING","sponsor":"University of Birmingham","startDate":"2019-10-25","conditions":"Polycythemia Vera","enrollment":586},{"nctId":"NCT04707235","phase":"","title":"ESCORT-HU Extension: European Sickle Cell Disease Cohort - Hydroxyurea - Extension Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Theravia","startDate":"2020-08-21","conditions":"Sickle Cell Disease","enrollment":2093},{"nctId":"NCT03825341","phase":"PHASE2","title":"Hydroxyurea Therapy: Optimizing Access in Pediatric Populations Everywhere","status":"TERMINATED","sponsor":"St. Jude Children's Research Hospital","startDate":"2019-06-10","conditions":"Sickle Cell Disease, Thalassemia","enrollment":1},{"nctId":"NCT02522104","phase":"PHASE4","title":"Evaluation of the Impact of Renal Function on the Pharmacokinetics of SIKLOS ® (DARH)","status":"COMPLETED","sponsor":"Theravia","startDate":"2015-09-03","conditions":"Sickle Cell Disease, Renal Function Disorder","enrollment":40},{"nctId":"NCT05025072","phase":"PHASE1","title":"A Bioequivalence Study to Compare the Pharmacokinetics of Two Formulations of Siklos® in Healthy Volunteers","status":"COMPLETED","sponsor":"Theravia","startDate":"2021-08-22","conditions":"Healthy Volunteers","enrollment":28},{"nctId":"NCT02962388","phase":"PHASE2, PHASE3","title":"The Ruxolitinib Versus Best Available Therapy Trial in Patients With High Risk ET in Second Line","status":"TERMINATED","sponsor":"French Innovative Leukemia Organisation","startDate":"2017-01-03","conditions":"Essential Thrombocythemia","enrollment":13},{"nctId":"NCT00468169","phase":"PHASE2","title":"Cetuximab (ERBITUX®) Added to Two Concurrent Chemoradiotherapy Platforms in Locally Advanced Head and Neck Cancer","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2006-07","conditions":"Head and Neck Cancer","enrollment":110},{"nctId":"NCT03547154","phase":"PHASE2, PHASE3","title":"Polyethylene Glycol Interferon Alfa-2b (PEG Intron) Versus Interferon Alfa-2b (INTRON^® A) in the Treatment of Newly Diagnosed Chronic Myelogenous Leukemia (CML) (C98026)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"1998-10-22","conditions":"Chronic Myelogenous Leukemia","enrollment":344},{"nctId":"NCT01506544","phase":"PHASE1","title":"Pharmacokinetics (PK) of Liquid Hydroxyurea in Pediatric Patients With Sickle Cell Anemia","status":"COMPLETED","sponsor":"Children's Mercy Hospital Kansas City","startDate":"2011-12","conditions":"Sickle Cell Anemia","enrollment":39},{"nctId":"NCT00333840","phase":"PHASE3","title":"Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2000-06","conditions":"Chronic Myelogenous Leukemia","enrollment":1106},{"nctId":"NCT01609192","phase":"PHASE4","title":"Future of Spermatogenesis in Men With Sickle Cell Disease Medically Treated","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2010-04","conditions":"Drepanocytic Men Treated by Hydroxyurea for the First Time","enrollment":50},{"nctId":"NCT00290771","phase":"PHASE2","title":"Efficacy and Safety of Imatinib Mesylate Plus Hydroxyurea (HU) in Patients With Recurrent Glioblastoma Multiforme (GBM)","status":"TERMINATED","sponsor":"Novartis","startDate":"2006-02","conditions":"Recurrent Glioblastoma Multiforme (GBM)","enrollment":231},{"nctId":"NCT00154375","phase":"PHASE3","title":"Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2004-10","conditions":"Glioblastoma Multiforme, Astrocytoma","enrollment":240}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Hydrea® (hydroxyurea )","genericName":"Hydrea® (hydroxyurea )","companyName":"Assistance Publique - Hôpitaux de Paris","companyId":"assistance-publique-h-pitaux-de-paris","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Hydroxyurea inhibits ribonucleotide reductase, reducing deoxyribonucleotide synthesis and slowing DNA replication in rapidly dividing cells. Used for Chronic myeloid leukemia (CML), Polycythemia vera, Essential thrombocythemia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}